Mottok, Anja

Molecular and genetic characterization of MHC deficiency identifies EZH2 as therapeutic target for enhancing immune recognition

Ennishi, D., Takata, K., Béguelin, W., Duns, G., Mottok, A., Farinha, P., Bashashati, A., Saberi, S., Boyle, M., Meissner, B., et al. (2019) · Cancer Discovery

Lymphoma Diagnosis and TreatmentCancer Immunotherapy and Biomarkers

Cited by 318

Selective inhibition of HDAC3 targets synthetic vulnerabilities and activates immune surveillance in lymphoma

Mondello, P., Tadros, S., Teater, M., Fontan, L., Chang, A. Y., Jain, N., Yang, H., Singh, S., Ying, H.-Y., Chu, C.-S., et al. (2020) · Cancer Discovery

Histone Deacetylase Inhibitors ResearchLymphoma Diagnosis and Treatment

Cited by 167

Inactivating SOCS1 mutations are caused by aberrant somatic hypermutation and restricted to a subset of B-cell lymphoma entities

Mottok, A., Renné, C., Seifert, M., Oppermann, E., Bechstein, W., Hansmann, M.-L., Küppers, R., & Bräuninger, A. (2009) · Blood

Lymphoma Diagnosis and TreatmentCytokine Signaling Pathways and Interactions

Cited by 124